Literature DB >> 3556280

Progression of incipient diabetic retinopathy during good glycemic control.

R L Engerman, T S Kern.   

Abstract

To assess the extent to which the progression of diabetic retinopathy can be arrested by improved glycemic control, 35 normal dogs were randomly divided into a nondiabetic and three alloxan-induced diabetic groups prospectively identified according to glycemic control: poor control for 5 yr (PC), good control for 5 yr (GC), and poor control for 2.5 yr followed by good control for 2.5 yr (PGC). To achieve good control, insulin was given twice daily together with a measured diet so that hyperglycemia and glucosuria were mild and infrequent, and HbA1 was comparable to normal. Retinal capillary aneurysms and other lesions developed during 60 mo of poor control (group PC) and were inhibited if good control was begun promptly within 2 mo (group GC). In group PGC, retinopathy was absent or equivocal at 2.5 yr of poor control and, surprisingly, was found to develop subsequently despite good glycemic control. Retinopathy in group PGC was greater at autopsy than at 2.5 yr and was greater than in group GC. The results indicate that retinopathy may be preventable but tends to resist arrest even in its incipient stages, before more than the first few aneurysms have appeared.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556280     DOI: 10.2337/diab.36.7.808

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  149 in total

1.  Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes.

Authors:  Renu A Kowluru; Qing Zhong; Mamta Kanwar
Journal:  Exp Eye Res       Date:  2010-02-17       Impact factor: 3.467

2.  Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid.

Authors:  Julia M Santos; Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-11       Impact factor: 4.799

Review 3.  Epigenetic mechanisms in diabetic complications and metabolic memory.

Authors:  Marpadga A Reddy; Erli Zhang; Rama Natarajan
Journal:  Diabetologia       Date:  2014-12-07       Impact factor: 10.122

4.  Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy.

Authors:  M A Di Leo; S Caputo; B Falsini; V Porciatti; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

Review 5.  Retinal ganglion cells in diabetes.

Authors:  Timothy S Kern; Alistair J Barber
Journal:  J Physiol       Date:  2008-06-19       Impact factor: 5.182

Review 6.  Hyperglycemia and vascular metabolic memory: truth or fiction?

Authors:  Cristina Bianchi; Roberto Miccoli; Stefano Del Prato
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

7.  The timing of re-institution of good blood glucose control affects apoptosis and expression of Bax and Bcl-2 in the retina of diabetic rats.

Authors:  Xin-Yuan Gao; Hong-Yu Kuang; Wei Zou; Xiao-Min Liu; Hong-Bin Lin; Yi Yang
Journal:  Mol Biol Rep       Date:  2008-11-08       Impact factor: 2.316

8.  Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats.

Authors:  H P Hammes; S S Ali; M Uhlmann; A Weiss; K Federlin; K Geisen; M Brownlee
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

9.  Insulin treatment normalizes retinal neuroinflammation but not markers of synapse loss in diabetic rats.

Authors:  Dustin R Masser; Heather D VanGuilder Starkey; Georgina V Bixler; Wendy Dunton; Sarah K Bronson; Willard M Freeman
Journal:  Exp Eye Res       Date:  2014-06-12       Impact factor: 3.467

10.  Relationship between early metabolic control and the development of microalbuminuria--a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Rudberg; E Ullman; G Dahlquist
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.